細胞名稱

人T淋巴瘤細胞SUP-T1

貨物編碼

BFN60803945

產品規格

T25培養瓶x1

1.5ml凍存管x2

細胞數量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研           1類

培養體系

DMEM高糖培養基（Hyclone）+10%胎牛血清（Gibco）+1%雙抗（Hyclone）

培養溫度

37℃

二氧化碳濃度

5%

簡介

人T淋巴瘤細胞SUP-T1來源8歲男性患者，懸浮培養，形態偏圓,少部分細胞呈現多邊形，此為正常現象。該細胞引種自ATCC CRL-1942

注釋

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Characteristics: Useful in studies of cell fusion and cytopathic effects of HIV-1 as well as cytopathic isolates of HIV-2.

Characteristics: Has chromosomal translocations involving the genes for the alpha and beta subunits of TCR thus preventing surface expression of the endogenous TCR complex.

Doubling time: 28 hours (PubMed=3004618); ~30 hours (DSMZ); ~24-36 hours (NIH-ARP).

Microsatellite instability: Stable (MSS) (Sanger); Instable (MSI) (PubMed=31068700).

Omics: Deep exome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

Omics: Virome analysis using RNAseq.

Derived from sampling site: Pleural effusion.

STR信息

Amelogenin        X,Y (ATCC; Cosmic-CLP)

X (DSMZ)

CSF1PO        10,11

D5S818        11,12 (ATCC; Cosmic-CLP)

10,11,12 (DSMZ)

D7S820        11

D13S317        11,12 (ATCC; Cosmic-CLP)

10,11,12 (DSMZ)

D16S539        9,11,12 (ATCC; Cosmic-CLP)

9,10,11 (DSMZ)

TH01        9.3

TPOX        9 (ATCC; Cosmic-CLP)

8,9 (DSMZ)

vWA        16,18 (ATCC; Cosmic-CLP)

16,18,19 (DSMZ)

參考文獻

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=30285677; DOI=10.1186/s12885-018-4840-5

Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

BMC Cancer 18:940-940(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)